IMUNON, Inc. (NASDAQ: IMNN), a
clinical-stage drug-development company focused on developing
non-viral DNA-mediated immuno-oncology therapies and
next-generation vaccines, today announced financial results for the
three and nine months ended September 30, 2023. The Company also
provided an update on its clinical development programs with
IMNN-001 (formerly GEN-1), a DNA-based interleukin-12 (IL-12)
immunotherapy in Phase 2 clinical development for the treatment of
first-line locally advanced ovarian cancer; on its PlaCCine
modality, a proprietary mono- or multi-cistronic non-viral and
synthetic DNA technology for the expression of pathogen antigens in
preclinical studies for the development of next-generation
vaccines; and on the early developments with its new FixPlas
modality for cancer vaccines.
Highlights of the third quarter of 2023 and
recent weeks include:
- Reported promising interim
progression-free survival (PFS) and overall survival (OS) data with
IMNN-001 in the Phase 1/2 OVATION 2 Study in advanced ovarian
cancer. Interim data from the intent-to-treat (ITT) population
showed efficacy trends in PFS, demonstrating a delay in disease
progression in the treatment arm of approximately 33% compared with
the control arm and preliminary OS data following a similar trend,
showing an approximate nine-month improvement in the treatment arm
over the control arm
- Enrolled the first patient in a
Phase 1/2 clinical trial evaluating IMNN-001 in combination with
bevacizumab in advanced ovarian cancer at the University of Texas
MD Anderson Cancer Center
- Continued on track to submit an
Investigational New Drug (IND) application in the first quarter of
2024 for a Phase 1/2 trial with IMNN-101, a seasonal COVID-19
booster vaccine, following positive pre-IND feedback from the U.S.
Food and Drug Administration (FDA)
- Presented updated promising data on
IMNN-101 at the 3rd Annual World Vaccines Congress
- Entered into a Cooperative
Research and Development Agreement (CRADA) with
the National Institute of Allergy and Infectious
Diseases (NIAID) to evaluate the immunogenicity and efficacy
of PlaCCine DNA vaccine constructs against Lassa virus in guinea
pig and non-human primate disease models
- Held a virtual R&D Day with
presentations by management and key opinion leaders (KOLs) on
cancer and infectious disease vaccines
- Reported cash and cash equivalents
of $19.5 million as of September 30, 2023
“The third quarter and recent weeks have been
marked by excellent progress across all our platform modalities,”
said Dr. Corinne Le Goff, IMUNON’s president and chief executive
officer. “We reported interim data from our Phase 1/2 OVATION 2
Study that showed patients treated with a PARP inhibitor (PARPi) as
maintenance therapy had longer PFS and OS if they were also treated
with IMNN-001, compared with patients treated with neoadjuvant
chemotherapy (NACT) only. This is not a pre-specified subgroup as
PARP inhibitors were approved after this study was initiated.
Although a small subgroup, the data support continued development
and suggest that IMNN-001 may have a place in new treatment
regimens and important commercial value. We expect to report final
topline results in mid-2024.”
“Interest in IMNN-001 continues to be strong,”
Dr. Le Goff continued, “as evidenced by the initiation of a Phase
1/2 clinical trial in advanced ovarian cancer in combination with
bevacizumab, or Avastin, at the University of Texas MD Anderson
Cancer Center. We are looking forward to adding prestigious cancer
sites to this study, along with driving enrollment in this research
with mainly third-party funding.”
“Development of our PlaCCine modality reached
important milestones with confirmation of PlaCCine versatility as a
plug-and-play modality by demonstrating preclinically the
immunogenicity and safety of our vaccines against many pathogens of
concern including COVID-19, Marburg, Lassa, monkeypox and influenza
viruses. We expect to file our IND application and begin patient
enrollment in a Phase 1/2 trial in the first half of 2024 for
IMNN-101, a next-generation COVID-19 seasonal booster.”
“Our DNA infectious disease vaccines are well
positioned to become the next generation of vaccines. I am excited
about their potential with the preclinical demonstration of more
durable antigen expression and T-cell responses versus protein and
mRNA vaccines, and better antibody response kinetics following a
single dose. In addition, our vaccines offer superior commercial
handling and distribution properties versus mRNA vaccines, as well
as greater manufacturing flexibility with better shelf-life of at
least 12 months at 4°C, one month at room temperature and at least
two weeks at 37°C. Our DNA cancer vaccines modality, FixPlas, is
equally well positioned to play an important role in a new era of
immunotherapy, with promising results in a mouse melanoma
model.”
Dr. Le Goff concluded, “With exciting and deep
technology directed toward important medical problems, IMUNON has a
promising future. The collaborations we formed this year are a
blueprint for future partnerships, particularly those with shared
development expenses.”
RECENT DEVELOPMENTS
IMNN-001 Immunotherapy
Reported Interim PFS and OS Data in
OVATION 2 Study in Advanced Ovarian Cancer. In September
2023, the Company announced interim PFS and OS data with IMNN-001
in its OVATION 2 Study. This study is evaluating the dosing,
safety, efficacy and biological activity of intraperitoneal
IMNN-001 in combination with NACT in patients newly diagnosed with
advanced epithelial ovarian, fallopian tube or primary peritoneal
cancer. NACT is designed to shrink the tumors as much as possible
for optimal surgical removal after three cycles of chemotherapy.
Following NACT, patients undergo interval debulking surgery,
followed by three additional cycles of chemotherapy to treat any
residual tumor.
The study is directional and designed with an
80% confidence interval to show an approximate 33% improvement in
PFS, when comparing the treatment arm (NACT + IMNN-001) with the
control arm (NACT only). The secondary endpoints include OS,
objective response rate (ORR), pathological response, surgical
response and serologic response. The final readout of this study is
expected in mid-2024. A positive readout would inform next
development steps.
- Interim data from the ITT
population showed efficacy trends in PFS, demonstrating a delay in
disease progression in the treatment arm of approximately 33%
compared with the control arm, with the hazard ratio nearing the
per protocol value. Preliminary OS data follows a similar trend,
showing an approximate nine-month improvement in the treatment arm
over the control arm.
- Subgroup analyses show patients
treated with a PARPi as maintenance therapy had longer PFS and OS
if they were also treated with IMNN-001, compared with patients
treated with NACT only.
- The median PFS in the PARPi + NACT
group and the PARPi + NACT + IMNN-001 group was 15.7 months and
23.7 months, respectively.
- The median OS in the PARPi + NACT
group was 45.6 months and has not yet been reached in the PARPi +
NACT + IMNN-001 group.
Continued benefits were seen in other secondary
endpoints including an approximately 20% higher R0 tumor resection
score and a doubling of the CRS 3 chemotherapy response score to
approximately 30% in the treatment arm, versus 14% in the control
arm. A complete tumor resection (R0) is a microscopically
margin-negative resection in which no gross or microscopic tumor
remains in the tumor bed. Chemotherapy response score is considered
a good prognostic indicator in ovarian cancer. Safety analyses
continue to show good tolerability of IMNN-001 in this setting.
Began Treatment in a Phase 1/2 Clinical
Trial Evaluating IMNN-001 in Combination with Bevacizumab in
Advanced Ovarian Cancer. In October 2023, the first
patient was enrolled in this trial at the University of Texas MD
Anderson Cancer Center, which is expected to enroll 50 patients
with Stage III/IV ovarian cancer. Patients undergoing frontline
neoadjuvant therapy will be randomized 1:1 to receive standard
chemotherapy plus bevacizumab, or standard chemotherapy plus
bevacizumab and IMNN-001. The trial’s primary endpoint is detection
of minimal residual disease (MRD) by second look laparoscopy (SLL),
and the secondary endpoint is PFS. Initial SLL data are expected
within one year following the completion of enrollment and final
PFS data are expected approximately three years following the
completion of enrollment. This trial will also include a wealth of
translational endpoints aimed at understanding the clonal evolution
and immunogenomic features of the MRD phase of ovarian cancer that
is currently undetectable by imaging or tumor markers.
PlaCCine: Developing the Prophylactic
Vaccines of the Future
Chief Science Officer Presented at the
3rd International Vaccines
Congress. In October 2023, Khursheed Anwer, Ph.D.
delivered a presentation titled “A DNA-based Vaccine Technology
Independent of Virus or Device,” which described the multiple
advantages of the PlaCCine modality over current commercial vaccine
platforms. The presentation also described the versatility of the
PlaCCine modality, demonstrating the activity against Marburg and
influenza viruses in collaboration with the Wistar Institute, and
activity against Lassa virus being evaluated at the NIH/NIAID.
Entered into a CRADA for Preclinical
Studies of the PlaCCine Modality in Preventive Vaccines Against
Lassa Virus. In August 2023, the Company announced it
entered into a CRADA with the NIAID to evaluate the
immunogenicity and efficacy of two IMUNON DNA-based Lassa virus
vaccine candidates in animal models. Under the three-year
agreement, the NIAID will assess the efficacy of PlaCCine DNA
constructs against Lassa virus in guinea pig and non-human primate
disease models, including both prime and prime-boost vaccine
strategies. The Laboratory of Virology at the NIAID is
researching a potential solution for combatting this
life-threatening pathogen by evaluating a DNA-based vaccine
approach for the treatment of the Lassa virus due to its durable
antigen expression, longer shelf-life at workable, standard
refrigerated temperatures and flexible manufacturing to potentially
address the limitations of current commercial products,
particularly in developing countries.
Preclinical Data with PlaCCine DNA-based
Vaccines Modality Published Online on bioRxiv. In August
2023, a manuscript titled “Strong immunogenicity & protection
in mice with PlaCCine: A COVID-19 DNA vaccine formulated with a
functional polymer” was published on the preprint server bioRxiv
[here]. The study used IMUNON’s proprietary formulation against the
spike proteins from two SARS-CoV-2 variants, both alone and in
combination. These results add to the growing body of preclinical
data confirming the efficacy and desirable features of IMUNON’s
PlaCCine vaccine modality. Data from the study show:
- IMUNON’s proprietary formulation of
functionalized polymer protected DNA from degradation, while the
combination with an adjuvant led to an increase in protein
expression
- DNA formulated with PlaCCine
resulted in a DNA vaccine product that was stable for up to one
year at 4°C, one month at room temperature and over two weeks at
38°C
- DNA formulated in PlaCCine resulted
in the induction of spike-specific neutralizing antibodies and
cytotoxic T cells
- In the in vivo challenge model, the
vaccine-induced immune response was capable of suppressing viral
replication
- Multiple inserts can be cloned into
the PlaCCine backbone (a plug-and-play strategy), therefore
allowing for an immune response with broader protection
Corporate Developments
Hosted a Virtual R&D Day.
In September 2023, IMUNON management along with guest KOLs in
immuno-oncology and vaccine development held a virtual R&D Day
to discuss the Company’s progress in developing its PlaCCine
platform, IMNN-001 and other achievements. IMUNON’s speakers
included Dr. Le Goff and Dr. Anwer. Guest KOL presenters
included:
- Sallie Permar, M.D., Ph.D., Chair
of the Department of Pediatrics at Weill Cornell Medicine
and Pediatrician-in-Chief at New York-Presbyterian/Weill
Cornell Medical Center and New York-Presbyterian Komansky
Children’s Hospital.
- Patrick Ott, M.D., Ph.D., Clinical
Director of the Melanoma Disease Center and the Director, Clinical
Sciences, of the Center for Immuno-Oncology at
the Dana-Farber Cancer Institute.
Dr. Permar’s presentation focused on the
“Vaccines of the Future” while Dr. Ott discussed
“Immuno-Oncology: The remaining unmet need.” A webcast of the event
is available in the Scientific Presentations section of
IMUNON’s website or here.
Expanded Scientific Advisory Board with
the Addition of Dr. Patrick Ott and Dr. Sachet
Shukla. They join current scientific advisory board
members Dan H. Barouch, M.D., Ph.D., Luke D. Handke,
Ph.D. and John W. Shiver, Ph.D. As the Company advances
FixPlas and IndiPlas into universal and personalized cancer
vaccines, Drs. Ott and Shukla will provide invaluable
assistance.
THIRD QUARTER FINANCIAL
RESULTS
IMUNON reported a net loss for the third quarter
of 2023 of $3.5 million, or $0.37 per share, compared with a net
loss of $6.1 million, or $0.87 per share, for the third quarter of
2022. Operating expenses were $3.9 million for the third quarter of
2023, a decrease of $2.4 million, or 38%, from $6.3 million for the
third quarter of 2022.
Net cash used for operating activities was $4.5
million for the third quarter of 2023 compared with $4.6 million
for the comparable prior-year period. The decrease was primarily
due to the decrease in net loss and change in accounts payable.
Cash provided by financing activities of $0.1 million during the
third quarter of 2023 resulted from equity sales under the
Company’s At-the-Market Equity Facility. The Company had $19.5
million in cash, investments and accrued interest receivable
as of September 30, 2023. The Company also has approximately $1.8
million of future planned sales of its State of New Jersey net
operating losses ($1.5 million in 2023 and $300,000 in 2024).
Research and development (R&D) expenses were
$2.0 million for the third quarter of 2023 compared with $2.4
million for the comparable period in 2022. R&D costs to support
the OVATION 2 Study as well as the Phase 3 OPTIMA Study decreased
to $0.1 million for the third quarter of 2023 compared with $0.6
million for the same period of 2022. Other clinical and regulatory
costs were $0.3 million for the third quarter of 2023 compared with
$0.4 million for the third quarter of 2022. R&D costs
associated with the preclinical development of the PlaCCine DNA
vaccine modality increased to $0.8 million for the third quarter of
2023 compared with $0.5 million for the same period of 2022.
R&D costs associated with the preclinical development of
IMNN-001 decreased to $0.3 million for the third quarter of 2023
compared with $0.6 million for the same period of 2022. Chemistry,
manufacturing and controls (CMC) costs increased to $0.5 million
for the third quarter of 2023 compared with $0.3 million for the
third quarter of 2022 due to higher costs related to the
development of in-house pilot manufacturing capabilities for DNA
plasmids and nanoparticle delivery systems.
General and administrative expenses were $1.9
million for the third quarter of 2023 compared with $3.9 million
for the comparable prior-year period. The decrease was primarily
due to lower non-cash stock-compensation expense and lower
professional fees, including legal fees to defend various lawsuits
filed after the announcement in July 2020 of the Phase 3 OPTIMA
Study results, offset by higher compensation expenses related to
the CEO succession plan announced in July 2022 and higher staffing
costs.
Other non-operating income was $0.4 million for
the third quarter of 2023 compared with $26 thousand for the
prior-year period. This increase was due to higher investment
income from the Company’s short-term investments.
NINE MONTH FINANCIAL
RESULTS
For the nine months ended September 30, 2023,
the Company reported a net loss of $14.6 million, or $1.64 per
share, compared with a net loss of $22.7 million, or $3.42 per
share, for the same period of 2022. Operating expenses were $15.1
million for the first nine months of 2023, a decrease of $3.3
million, or 18%, from $18.4 million for the same period of
2022.
Net cash used for operating activities was $15.3
million for the first nine months of 2023 compared with $18.1
million for the same period in 2022. The decrease was primarily due
to the one-time payment of $4.5 million in interest expense
resulting from the sale and subsequent redemption of $30 million of
Series A & B convertible redeemable preferred stock in the
first quarter of 2022. Cash used by financing activities of $3.7
million during the first nine months of 2023 resulted from the
early repayment of the Company’s loan facility with Silicon Valley
Bank ($6.4 million), offset by sales of equity under the Company’s
At-the-Market Equity Facility ($2.8 million). The Company also
received net proceeds of $1.6 million from the sale of its unused
New Jersey NOLs in the first quarter of 2023.
R&D expenses were $7.7 million for the first
nine months of 2023 compared with $8.7 million for the comparable
period in 2022. R&D costs to support the OVATION 2 Study as
well as the Phase 3 OPTIMA Study decreased to $0.7 million for the
first nine months of 2023 compared with $2.2 million for the
comparable 2022 period. Other clinical and regulatory costs were
$1.1 million for the first nine months of 2023 compared with $1.7
million for the same period of 2022. R&D costs associated with
the preclinical development of the PlaCCine DNA vaccine modality
increased to $3.1 million for the first nine months of 2023
compared with $1.6 million for the same period of 2022. R&D
costs associated with the preclinical development of IMNN-001
decreased to $1.0 million for the first nine months of 2023
compared with $2.4 million for the same period of 2022. CMC costs
increased to $1.8 million for the first nine months of 2023
compared with $0.9 million for the comparable 2022 period due to
higher costs related to the development of in-house pilot
manufacturing capabilities for DNA plasmids and nanoparticle
delivery systems.
General and administrative expenses were $7.3
million for the first nine months of 2023 compared with $9.6
million for the same period of 2022. The $2.3 million decrease was
primarily due to lower non-cash stock-compensation expense and
lower professional fees, including legal fees to defend various
lawsuits filed after the announcement in July 2020 of the Phase 3
OPTIMA Study results, offset by higher compensation expenses
related to the CEO succession plan and higher staffing costs.
Other non-operating income was $0.4 million for
the first nine months of 2023 compared with $4.7 million for the
comparable prior-year period. The decrease was primarily
attributable to the one-time payment of $4.5 million in interest
expense resulting from the sale and subsequent redemption of $30
million of Series A & B convertible redeemable preferred stock
in the first quarter of 2022.
CONFERENCE CALL AND WEBCAST
The Company is hosting a conference call to
provide a business update, discuss third quarter 2023 financial
results and answer questions at 10:00 a.m. ET today. To participate
in the call, please dial 866-777-2509 (Toll-Free/North America) or
412-317-5413 (International/Toll) and ask for the IMUNON Third
Quarter 2023 Earnings Call. A live webcast of the call will be
available here.
The call will be archived for replay until
November 28, 2023. The replay can be accessed at 877-344-7529 (U.S.
Toll-Free), 855-669-9658 (Canada Toll-Free) or 412-317-0088
(International Toll), using the replay access code 7035449. A
webcast of the call will be available here for 90 days.
About IMUNON
IMUNON is a fully integrated, clinical-stage
biotechnology company focused on advancing a portfolio of
innovative treatments that harness the body’s natural mechanisms to
generate safe, effective and durable responses across a broad array
of human diseases, constituting a differentiating approach from
conventional therapies. IMUNON is developing its non-viral DNA
technology across four modalities. The first modality, TheraPlas®,
is developed for the coding of proteins and cytokines in the
treatment of solid tumors where an immunological approach is deemed
promising. The second modality, PlaCCine®, is developed for the
coding of viral antigens that can elicit a strong immunological
response. This technology may represent a promising platform for
the development of vaccines in infectious diseases. The third
modality, FixPlas®, concerns the application of our DNA technology
to produce universal cancer vaccines, also called tumor associated
antigen cancer vaccines. The fourth modality, IndiPlas®, is in the
discovery phase and will focus on the development of personalized
cancer vaccines, or neoepitope cancer vaccines.
The Company’s lead clinical program, IMNN-001,
is a DNA-based immunotherapy for the localized treatment of
advanced ovarian cancer currently in Phase 2 development. IMNN-001
works by instructing the body to produce safe and durable levels of
powerful cancer-fighting molecules, such as interleukin-12 and
interferon gamma, at the tumor site. Additionally, the Company is
conducting IND-enabling preclinical studies for the development of
a COVID-19 booster vaccine (IMNN-101) and a treatment for the LASSA
virus (IMNN-102). The Company has also initiated preclinical work
to develop a Trp2 tumor associated antigen cancer vaccine in
melanoma (IMNN-201). We will continue to leverage these modalities
and to advance the technological frontier of plasmid DNA to better
serve patients with difficult-to-treat conditions. For more
information on IMUNON, visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that
forward-looking statements in this news release are made pursuant
to the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. Readers are cautioned that such
forward-looking statements involve risks and uncertainties
including, without limitation, unforeseen changes in the course of
research and development activities and in clinical trials; the
uncertainties of and difficulties in analyzing interim clinical
data; the significant expense, time and risk of failure of
conducting clinical trials; the need for IMUNON to evaluate its
future development plans; possible acquisitions or licenses of
other technologies, assets or businesses; possible actions by
customers, suppliers, competitors or regulatory authorities; and
other risks detailed from time to time in IMUNON’s periodic reports
and prospectuses filed with the Securities and Exchange Commission.
IMUNON assumes no obligation to update or supplement
forward-looking statements that become untrue because of subsequent
events, new information or otherwise.
Contacts:
IMUNON |
LHA Investor Relations |
Jeffrey W. Church |
Kim Sutton Golodetz |
Executive Vice President, CFO |
212-838-3777 |
609-482-2455 |
Kgolodetz@lhai.com |
jchurch@imunon.com |
|
(Tables to Follow)
IMUNON, Inc.Condensed
Statements of Operations(in thousands except per
share amounts)
|
|
Three Months EndedSeptember
30, |
|
|
Nine Months EndedSeptember
30, |
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Licensing
revenue |
|
$ |
- |
|
|
$ |
125 |
|
|
$ |
- |
|
|
$ |
375 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
1,981 |
|
|
|
2,408 |
|
|
|
7,735 |
|
|
|
8,730 |
|
General and administrative |
|
|
1,923 |
|
|
|
3,891 |
|
|
|
7,328 |
|
|
|
9,640 |
|
Total operating expenses |
|
|
3,904 |
|
|
|
6,299 |
|
|
|
15,063 |
|
|
|
18,370 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations |
|
|
(3,904 |
) |
|
|
(6,174 |
) |
|
|
(15,063 |
) |
|
|
(17,995 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investment and other income |
|
|
427 |
|
|
|
153 |
|
|
|
962 |
|
|
|
207 |
|
Interest expense |
|
|
- |
|
|
|
(127 |
) |
|
|
(197 |
) |
|
|
(4,878 |
) |
Loss on debt extinguishment |
|
|
- |
|
|
|
- |
|
|
|
(329 |
) |
|
|
- |
|
Total other (expense) income, net |
|
|
427 |
|
|
|
26 |
|
|
|
436 |
|
|
|
(4,671 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(3,477 |
) |
|
$ |
(6,148 |
) |
|
$ |
(14,627 |
) |
|
$ |
(22,666 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per common share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
$ |
(0.37 |
) |
|
$ |
(0.87 |
) |
|
$ |
(1.64 |
) |
|
$ |
(3.42 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average
shares outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
|
9,377 |
|
|
|
7,099 |
|
|
|
8,926 |
|
|
|
6,622 |
|
IMUNON, Inc.Selected
Balance Sheet Information(in
thousands)
ASSETS |
|
September 30, 2023 |
|
|
December 31, 2022 |
|
Current assets |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
12,884 |
|
|
$ |
11,493 |
|
Investment securities and interest receivable |
|
|
6,590 |
|
|
|
21,384 |
|
Money market investments, restricted cash |
|
|
- |
|
|
|
1,500 |
|
Advances, deposits and other current assets |
|
|
2,251 |
|
|
|
2,403 |
|
Total current assets |
|
|
21,725 |
|
|
|
36,780 |
|
|
|
|
|
|
|
|
|
|
Property and equipment |
|
|
824 |
|
|
|
548 |
|
|
|
|
|
|
|
|
|
|
Other assets |
|
|
|
|
|
|
|
|
Restricted cash invested in money market account |
|
|
- |
|
|
|
4,500 |
|
Deferred tax asset |
|
|
- |
|
|
|
1,567 |
|
Operating lease right-of-use assets |
|
|
1,664 |
|
|
|
156 |
|
Deposits and other assets |
|
|
441 |
|
|
|
425 |
|
Total other assets |
|
|
2,105 |
|
|
|
6,648 |
|
Total
assets |
|
$ |
24,654 |
|
|
$ |
43,976 |
|
LIABILITIES AND
STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
|
Accounts payable and accrued liabilities |
|
$ |
4,846 |
|
|
$ |
8,381 |
|
Note payable – current portion |
|
|
- |
|
|
|
1,425 |
|
Operating lease liabilities – current portion |
|
|
470 |
|
|
|
231 |
|
Total current liabilities |
|
|
5,316 |
|
|
|
10,037 |
|
|
|
|
|
|
|
|
|
|
Notes payable – noncurrent portion |
|
|
- |
|
|
|
4,611 |
|
Operating lease liabilities – noncurrent portion |
|
|
1,266 |
|
|
|
- |
|
Total
liabilities |
|
|
6,582 |
|
|
|
14,648 |
|
Stockholders’
equity |
|
|
|
|
|
|
|
|
Common stock |
|
|
94 |
|
|
|
74 |
|
Additional paid-in capital |
|
|
401,337 |
|
|
|
397,980 |
|
Accumulated other comprehensive gain (loss) |
|
|
20 |
|
|
|
27 |
|
Accumulated deficit |
|
|
(383,294 |
) |
|
|
(368,668 |
) |
|
|
|
18,157 |
|
|
|
29,413 |
|
Less: Treasury stock |
|
|
(85 |
) |
|
|
(85 |
) |
Total stockholders’
equity |
|
|
18,072 |
|
|
|
29,328 |
|
Total liabilities and
stockholders’ equity |
|
$ |
24,654 |
|
|
$ |
43,976 |
|
# # #
Imunon (NASDAQ:IMNN)
過去 株価チャート
から 4 2024 まで 5 2024
Imunon (NASDAQ:IMNN)
過去 株価チャート
から 5 2023 まで 5 2024